Generic Name and Formulations:
Frovatriptan (as succinate) 2.5mg; tabs.
Indications for FROVA:
Acute treatment of migraine.
≥18yrs: 2.5mg with fluids; may repeat once after 2 hours; max 7.5mg/24 hours. Reevaluate if no response after 1st dose. The safety of treating an average of more than 4 headaches in a 30-day period has not been established.
<18yrs: not recommended.
Ischemic cardiac, cerebro- or peripheral vascular disease (eg, history of MI, angina pectoris, silent myocardial ischemia, stroke, TIA, ischemic bowel disease). Uncontrolled hypertension. Other significant cardiovascular disease. Basilar or hemiplegic migraine. Within 24 hours of other 5-HT1 agonists or ergot-type drugs.
Confirm diagnosis. Exclude underlying cardiovascular disease, supervise 1st dose, consider monitoring ECG in patients with likelihood of unrecognized coronary disease (eg, postmenopausal women, men over age 40, hypertension, hypercholesterolemia, obesity, diabetes, smokers, strong family history). Monitor cardiovascular function in long-term intermittent use. Peripheral vascular or colonic ischemia after other 5-HT1 agonists. Severe hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Methysergide, other ergotamines, or other 5-HT1 agonists: see Contraindications. Serotonin syndrome with SSRIs (eg, fluoxetine, fluvoxamine, paroxetine, sertraline).
Selective 5-HT1B/1D receptor agonist.
Dizziness, paresthesia, dry mouth, fatigue, flushing, hot or cold sensation, dyspepsia, skeletal pain, chest/throat/neck symptoms (pain, pressure, tightness); serious cardiac events (rare).